Greg Rossi’s Post

Tomorrow, May 21st is the day. Join us for Pharma R&D Annual Review Webinar. Guaranteed to be informative and entertaining! #pharmaResearch #pharmaR&D #citeline, #researchanddevelopment

❓ What is market shaping and why is it so important? Our recent CapSys Group panel discussion about Biopharma product launches saw us tackle this topic, with the expert input of: - Luca Gazzi, Global Market Access & Pricing Lead at Sanofi - Klaus Viel, Innovation Leader Early Medical Affairs, Integrated Planning, and brand-agnostic services at Boehringer Ingelheim - Siddharth Jain, Medical Director, Global Medical Lead (Lysosomal Storage Diseases) at Takeda Our thanks to all of you for making the time to discuss these key topics - and we look forward to sharing these short recaps here over the coming weeks. P.S. If there are any topics you'd like to see covered in future panel discussions, please add them in the comments and we'll incorporate these suggestions accordingly. #BiopharmaIndustry #Pharmaceutical #ProductLaunch

Oligonucleotide Therapies (ONTs) Tracker Currently, there are 20 oligonucleotide drugs approved by the FDA and the European Medicines Agency and a majority of them treat orphan and rare diseases. Novartis, GSK, and Novo Nordisk have made significant investments in the ONT space. Last year, Astellas Pharma bought Iveric Bio for US$ 5.9 billion. View our interactive dashboard: https://lnkd.in/guwygS8a Read more at: https://lnkd.in/gMPKfQsT #PharmaFlow - Pharma Data Compilations by PharmaCompass.com #FDA #medicine #genetherapy #celltherapy #healthcare #rarediseases #pharmaceuticals #pharmanews #pharmaceuticalindustry #innovation #management #digitalmarketing #technology #startups #marketing #sales #strategy #networking #pharmacompass

🌟 Meet Dr. Hans Bock, MD: Chairman of Celero Global's Exclusive Advisory Board 🎊 We are delighted to welcome Dr. Hans Bock as the Chairman and Strategy Advisor of our esteemed and exclusive Advisory Board. With a distinguished career spanning over four decades in clinical research and development, Dr. Bock brings unparalleled expertise to his role. We are excited to have Dr. Bock at the helm of our exclusive Advisory Board, steering us with his visionary leadership and profound insights into the future of clinical research. #AdvisoryBoard #MeetTheTeam #ClinicalResearch #Biopharma #Biotech #CRO #PharmaInnovation #HealthcareLeadership #MedicalScience #DrugDevelopment #ClinicalTrials #LifeSciences #Biotechnology #PharmaIndustry #ResearchAndDevelopment #FutureOfHealthcare #PharmaCareers #Biomedical #Pharmaceuticals #ClinicalOperations #InnovativeMedicine #HealthTech #ScienceAndResearch #MedicalTechnology #BiopharmaNews #ClinicalTrialManagement #BiotechStartup #PharmaceuticalInnovation #MedicalResearch #HealthcareSolutions

Finding multiple use cases for your R&D investment plays a large role in de-risking your investment AND delivering a Return on Investment (ROI). Pharma, it turns out, has publicly available datasets that justify this conclusion. The data shows that thinking broadly about use case for a new compound is a critical component of an overall strategy for managing risk early in the investment phase. In pharma, early testing to find potential treatment indications for the compound gives you a number of 'shots on goal' as you look to spend over $1B to move your compound through clinical trials. When we investigated Roche, we saw that each New Molecule Entity (NME), as Roche defines them, had, on average, 7.5 indications and treatment modalities for each NME over our ten-year period. First, NME submissions for clinical trials were heavily biased towards oncology (see comment for our graph). When the first indication was not oncology, the majority of the time oncology was the second indication. This strategy outperforms others over the long run. Based on these observations, we can accurately predict Roche's next investments by knowing which phases of clinical trials it prefers. If you like insights like this, join us weekly at the 4x4 Innovation Group each Thursday @ 7AM Pacific where Martin Schweiger holds lively discussions with leading experts like Mike Rea on innovation strategies that ACTUALLY move the needle. Join us 𝐭𝐨𝐦𝐨𝐫𝐫𝐨𝐰 for the next 4x4 Innovation Meet to explore the latest developments across various industries: https://lnkd.in/gse8rcyA #innovationmanagement

Oligonucleotide Therapies (ONTs) Tracker Currently, there are 20 oligonucleotide drugs approved by the FDA and the European Medicines Agency and a majority of them treat orphan and rare diseases. Novartis, GSK, and Novo Nordisk have made significant investments in the ONT space. Last year, Astellas Pharma bought Iveric Bio for US$ 5.9 billion. View our interactive dashboard: https://lnkd.in/dWfMDYEg Read more at: https://lnkd.in/dGZ4sprw #PharmaFlow - Pharma Data Compilations by PharmaCompass.com #FDA #medicine #genetherapy #celltherapy #healthcare #rarediseases #pharmaceuticals #pharmanews #pharmaceuticalindustry #innovation #management #digitalmarketing #technology #startups #marketing #sales #strategy #networking #pharmacompass

⭐ Join the team at Citeline for an exclusive webinar titled "Pharma R&D Annual Review" on May 21, 2024, at 10 AM EDT. ⭐ What is it? Pharmaprojects’ annual review of trends in pharmaceutical R&D takes the temperature of the industry at the start of 2024 by assessing the pipeline by company, therapeutic area, disease, target, and emerging drug modalities and regional variations.    ⭐ What will you learn? An understanding of how the pharma R&D climate is changing, where the pressure is rising and falling, and determine which parts of the industry are likely to be basking in sunshine and which may be preparing for unsettled conditions. This original research uses the gold-standard dataset of Pharmaprojects to support clinical planning, competitive intelligence, and market landscape assessments.    Please follow this link below for more details and to register: Citeline Citeline Clinical Citeline Commercial https://lnkd.in/euwN_3zv

Embark on a fascinating journey with us as we unravel the captivating tales of ceftobiprole (Zevtera) and natalizumab, showcasing the intricate process of drug discovery and development. Ceftobiprole's remarkable history and natalizumab's pivotal role in treating multiple sclerosis (MS) offer profound insights into the pharmaceutical landscape's evolution. Join our community as we explore the complexities, challenges, and triumphs of drug development, from inception to FDA approval. Let's ignite discussions, share knowledge, and celebrate the innovative strides in healthcare. Discover the stories behind these groundbreaking drugs and gain a deeper understanding of their impact on global health. Together, let's embark on a journey of discovery and enlightenment! Don't miss out – like our page, engage with our content, and stay informed about the latest advancements in pharmaceuticals! 💊✨ VIDEO 1: CEFTOBIPROLE (ZEVTERA) JOURNEY: https://lnkd.in/dKSeZjTk VIDEO 2: DRUG DISCOVERY AND DEVELOPMENT (PART 1): https://lnkd.in/djiqXDeG #viralvideo #viral #video #viralvideos #pharmacist #pharmacystudents #pharmacyeducation #medicalstudent #researchanddevelopment #tysabri #zevtera #ceftobiprole #natalizumab #DrugDiscovery #PharmaInnovation #MedicalBreakthroughs #HealthcareProgress #Pharmaceuticals #InnovativeMedicine #BiotechAdvancements #DrugDevelopment #MedicalResearch #HealthcareInnovation #PharmaHistory #DrugApproval #ScienceAndMedicine #MedicalDiscoveries #InnovativeTherapies #PharmaIndustry #HealthcareEvolution #MedicalAdvancements #BiomedicalResearch #PharmaSuccess

📢 Are you interested in learning about the benefits and pitfalls of collaboration between patient organizations and pharmaceutical companies for developing treatments for rare and ultra-rare diseases? 💼 Check out our latest white paper, which includes a case study illustrating how a pragmatic and respectful approach can lead to successful outcomes for both parties. The paper also highlights the challenges, opportunities, and best practices involved in creating a successful collaboration between patient organizations and pharma. 🌍 At IQVIA, we're committed to driving healthcare forward and creating meaningful partnerships that benefit patients and the life sciences industry. Our white paper offers insights and recommendations for creating a successful collaboration between patient organizations and pharma. 💡 Download the white paper to learn about effective collaboration between patient organizations and pharma, and how it can drive innovation and improve outcomes for rare and ultra-rare disease patients: https://lnkd.in/e9XqJKqC #patientorganizations #pharmaceuticalcompanies #rarediseases #ultrararediseases

I am delighted to share this to my LinkedIn network that I have attended the one day National Conference on 'A Navigating Innovation and Career Paths in the Pharmaceutical Industry'🚧. In this conference I learnt about the Artificial Intelligence, Recent Trends, CRM in Pharmaceutical Industry and Healthcare Analytics🏥. I am trying to embark myself with the knowledge of new things in Pharmaceutical Industry🤓. #virtualconference #PHARMASUMMIT2024 #March2024 #LBSPune